Related Experiment Video
Updated: Feb 8, 2026

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
Published on: August 1, 2025
Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients
Artur Jurczyszyn1, Jorge J Castillo2, Irit Avivi3
1a Hematology Department , Jagiellonian University Medical College , Cracow , Poland.
Abstract:
This multicenter retrospective study included 101 patients (median age 62 years) with secondary plasma cell leukemia (sPCL). The median time from initial multiple myeloma diagnosis to sPCL was 31 months. Fifty-five out of 72 patients (75%) who received any therapy were treated with immunomodulators (IMiDs) and/or proteasome inhibitors (PIs), and 14/72 (19%) underwent salvage autologous stem cell transplantation (ASCT). The overall response rate in patients who received ASCT or PI (either alone or in combination) was higher than in those who did not (93% vs. 36% and 60% vs. 30%, respectively). The median overall survival (OS) in patients who received therapy was 4.2 months (95% CI: 1.3; 8.0) with a 1-year OS of 19%. Platelet count ≤100 × 109/L at sPCL diagnosis was the only independent predictor of a poorer OS in treated patients (HR = 3.98, p = .0001). These findings suggest that patients with sPCL may benefit from salvage ASCT- and PI-based regimens.
More Related Videos
Related Concept Videos
Secondary Active Transport
Secondary Active Transport
Primary and Secondary Growth in Roots and Shoots
Secondary Healthcare System
Secondary Distribution
In residential areas, 120/240 V single-phase, three-wire service is commonly used for lighting, outlets, and large appliances. Urban areas with high-density loads...
Protein Buffers in Blood Plasma and Cells
Certain amino acids can exist in a zwitterion state at a...

